创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

依达拉奉在经颅内血肿微创引流术后硬膜外血肿患者中的应用

Application of Edaravone in Patients with Epidural Hematoma after Minimally Invasive Drainage of Intracranial Hematoma

  • 摘要: 目的 探究经颅内血肿微创引流术治疗的硬膜外血肿患者,术后应用依达拉奉对其神经功能和血清炎症-氧化应激反应的影响。方法 前瞻性将102例经颅内血肿微创引流术治疗的硬膜外血肿患者随机分为常规组和依达拉奉组,各51例,对比2组手术相关指标以及血清炎症因子、氧化应激和炎症-氧化应激指标之间的差异,以美国国立卫生研究院卒中量表(National Institutes of HealthStroke Scale,NIHSS)和改良Barthel指数(modified Barthel index,MBI)分别评估患者神经功能和日常行动能力。结果 依达拉奉组住院时间较常规组明显缩短(P<0.05)。治疗后,依达拉奉组血清超敏C反应蛋白(high-sensitivity c-reactive protein,hsCRP)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白介素-6(interleukin-6,IL-6)、血清基质金属蛋白酶(matrixmetalloproteinase,MMP)-9/-12、血清同型半胱氨酸(homocysteine,Hcy)、丙二醛(malondialdehyde,MDA)含量及NIHSS评分明显低于常规组(P<0.05),超氧化物歧化酶(superoxide dismutase,SOD)、谷胱甘肽过氧化物酶(glutathioneperoxidase,GSH-Px)水平和MBI评分明显高于常规组(P<0.05)。结论 依达拉奉能够显著改善经颅内血肿微创引流术后硬膜外血肿患者的神经功能,降低炎症因子水平,增强抗氧化能力,提高患者的日常行动能力。

     

    Abstract: Objective This study aimed to explore the effects of edaravone on neurological function and the inflammation-oxidative stress response in patients with epidural hematoma treated with minimally invasive drainage of intracranial hematoma. Methods A total of 102 patients with epidural hematoma treated with minimally invasive drainage of intracranial hematoma were prospectively and randomly divided into a conventional treatment group and an edaravone group, with 51 cases in each group. The differences in serum inflammatory factors, oxidative stress, and inflammation-oxidative stress indicators between the two groups were compared. The National Institutes of Health Stroke Scale (NIHSS) and modified Barthel index (MBI) were used to evaluate patients, neurological function and daily mobility, respectively. Results The hospital stay was significantly shorter in the edaravone group compared to the conventional treatment group (P<0.05). After treatment, the levels of serum high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), matrix metalloproteinase (MMP)-9/-12, homocysteine (Hcy), malondialdehyde (MDA), and the NIHSS score in the edaravone group were significantly lower than those in the conventional treatment group (P<0.05). The levels of superoxide dismutase (SOD), glutathione peroxidase (GSH- Px), and MBI score were significantly higher in the edaravone group than those in the conventional treatmentl group (P<0.05). Conclusion Edaravone can significantly improve the neurological function of patients with epidural hematoma after minimally invasive drainage of intracranial hematoma, reduce the levels of inflammatory factors, enhance the antioxidant capacity, and improve patients, ability to perform daily activities.

     

/

返回文章
返回